Abstract
BackgroundIn Poland drug programmes developed by the Minister of Health and financed by the National Health Fund are special reimbursement frameworks of innovative, expensive, and mostly hospital based medical products used for a small number of patients.Research DesignThe research presented in this paper is based on data analysis published by the National Health Fund in Poland. The analysis focused on estimating public payer expenditure on drugs available within drug programmes from 2015 to 2018.ResultsIn subsequent years, reimbursement of drugs used within drug programmes was associated with the National Health Fund budget expenditure of 635 mln USD, 755 mln USD, 854 mln USD, and 921 mln USD, respectively. Reimbursement of oncology drug programmes constituted 48.1%, 42.5%, 47.1%, and 52.4% and were approximately 305, 312, 402, 483 mln USD, whereas values of non-oncology drug programmes were approximately 330, 434, 452, and 438 mln USD which constituted 51.9%, 57.5%, 52.9%, and 47.6% respectively.ConclusionDespite the fact that the expenditure on drug programs in Poland are increasing every year, they undoubtedly improve the patient’s access to the most innovative oncological and nononcological therapies in the Polish healthcare system.
Highlights
A drug reimbursement system in Poland is the constitutional response for providing access to health services by the country
The analysis focused on estimating public payer expenditure on drugs available within drug programmes during 2015–2018 in Poland and indication values of reimbursement realised by the National Health Fund in Poland (NHF) in terms of drug programmes divided into particular oncology and non-oncology drug programs
The research presented in this paper was based on analysis of data provided by the National Health Fund in Poland (NHF)
Summary
A drug reimbursement system in Poland is the constitutional response for providing access to health services by the country. The entitlement of a patient-beneficiary to guarantee services financed (cofinanced) from public funds entails, among others, a right to drugs. Poland is an example of a country where medicines cannot be reimbursed without formal procedures It is not possible for a drug to be reimbursed for a new medical indication without an assessment of health technologies. This concerns medicines that are available to patients as part of drug programs. In Poland drug programmes developed by the Minister of Health and financed by the National Health Fund are special reimbursement frameworks of innovative, expensive, and mostly hospital based medical products used for a small number of patients. The analysis focused on estimating public payer expenditure on drugs available within drug programmes from 2015 to 2018
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
